Vera Therapeutics VERA 深 沪
已收盘 08-14 16:00:00 美东时间
31.63
+2.740
+9.48%
华盛通- 最 高32.31
- 今 开31.29
- 成交量 587.58万股
- 最 低 29.73
- 昨 收 28.89
- 总市值 22.70亿
- 52周最高 56.05
- 市盈率 静 --
- 换手率 8.19%
- 52周最低 21.15
- 委 比 -24.75%
- 总股本 7178.29万
- 历史最高 56.05
- 量 比 4.00
- 振 幅 8.93%
- 历史最低 5.20
- 每 手 1
- 风险率 7.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Heartflow, Eton Pharmaceuticals, Nu Holdings And Other Big Stocks Moving Higher On Friday
U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Friday. Shares of Heartflow Inc (NASDAQ:HTFL) rose sharply after the company reported better-than-expected quarterly adjusted EPS results. HeartFlow reported quarterly losses of 7 cents per share which beat the analyst...
08-14 21:55
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34
Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and lowers the price target from $43 to $34.
08-11 21:39
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aura Biosciences reported Q2 2026 financial results and business updates, highlighting the full enrollment of its Phase 3 CoMpass trial for bel-sar in early choroidal melanoma, exceeding targets and on track for 2H 2027 topline data. The company refocused its strategic plan on ocular oncology, deprioritizing the NMIBC program while maintaining data collection. Organizational restructuring and leadership appointments were announced to align resour...
08-11 11:00
财报速睇 | Vera Therapeutics 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损1.09亿美元，同比亏损扩大43.0%
华盛资讯8月11日讯，Vera Therapeutics公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损1.09亿美元，同比亏损扩大43.0%。
08-11 06:06
Vera Therapeutics Q2 EPS $(1.52) Beats $(1.61) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.61) by 5.59 percent. This is a 26.67 percent decrease over losses of $(1.20) per share from the same period last year.
08-11 05:06
财报速睇 | Vera Therapeutics 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损1.09亿美元，同比亏损扩大43.0%
华盛资讯8月11日讯，Vera Therapeutics公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损1.09亿美元，同比亏损扩大43.0%。
08-11 04:20
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics granted inducement awards, including stock options and RSUs, to its new Chief Regulatory Officer Nancy Bowman and two other employees under the 2024 Inducement Plan. The awards, valued at Vera's closing stock prices on August 3 and 4, 2026, will vest over four years. Vera Therapeutics is a biotech company focused on autoimmune diseases, with its flagship product TRUTAKNA™.
08-07 20:05
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics于2026年7月6日授予8名新员工总计32,100股非合格股票期权及16,050股限制性股票单位（RSU），依据其2024年激励计划。股票期权行权价为每股40.13美元，归属期为4年，其中25%在首年归属，剩余部分在36个月内按月归属。RSU同样归属4年，每年8月20日归属25%。Vera Therapeutics是一家专注于自身免疫疾病的生物技术公司，总部位于加利福尼亚州布里斯班。
07-10 20:05
